Advertisement

Pathology & Oncology Research

, Volume 22, Issue 3, pp 461–470 | Cite as

Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma

  • Saba Mohamed El-GendiEmail author
  • Mohamed Farouk Mostafa
Original Article

Abstract

The Runx family of transcription factors has been implicated in cancer progression, both positively and negatively. Recent studies assigned a role for Runx2 in promoting breast cancer metastasis. However, the role of Runx2 during the early stage of breast carcinoma and its association with clinical outcomes remain unknown. Assessing the clinicopathological significance of Runx2 expression in a cohort of breast invasive ductal carcinomas (IDC). The correlation of nuclear Runx2 LI with clinicopathological parameters was assessed in 84 IDCs. To study the association of Runx2 with patient outcomes, in addition to treating it as a continuous variable, Runx2 was categorized by its median value (65) and by an additional two cut-off points determined by ROC curve analyses, at 45 for disease free survival (DFS) and 40 for overall survival (OS). Multivariate Cox regression models were also constructed. We used the best subset regression to identify models that predict DFS and OS with as few predictors as possible, and validation was performed. Based on the “Predicted R2”, the three best models were identified. Using Cox-regression, the interaction between Runx2 and other clinicopathological terms was tested. Runx2 LI was significantly associated only with positive Her-2 status, and did not correlate significantly with other clinicopathological parameters. Although Runx2 LI, in the continuous form and when categorized by the median, did not correlate significantly with DFS and OS; after it was categorized using the optimal cut-off points determined using ROC curve analysis, the patients with Runx2 LI >45 % showed a significantly higher event rate and shorter DFS (P = 0.047), whereas patients with Runx2 LI >40 % showed a significantly shorter OS (P = 0.050). Moreover, Runx2 LI contributed significantly in the models built to predict DFS and OS. For DFS, no interaction terms contributed significantly to the models. However, among stage IV cases, the interaction term between centred Runx2 and ER significantly contributed to the prediction of OS. Runx2 was a significant predictor of OS in this model. Runx2 has a role in biological behaviour and affects the outcome of IDC; therefore, its inhibition may be a new therapeutic strategy. The predictability of Runx2 for OS in stage IV tumours differs with different ER states. The pattern of this difference was not determined because the sample size was not sufficient to allow pattern testing.

Keywords

Runx2 Breast carcinoma Prognostic factor Clinical outcome Survival 

Notes

Acknowledgments

The authors appreciate all technicians at Department of Pathology, Alexandria University, Egypt.

Compliance with Ethical Standards

Conflict of Interest

The authors have no conflicts of interest.

Supplementary material

12253_2015_18_MOESM1_ESM.docx (24 kb)
Supplemental Table 1 (DOCX 24 kb)
12253_2015_18_MOESM2_ESM.docx (21 kb)
Supplemental Table 2 (DOCX 20 kb)
12253_2015_18_MOESM3_ESM.docx (21 kb)
Supplemental Table 3 (DOCX 20 kb)
12253_2015_18_MOESM4_ESM.docx (21 kb)
Supplemental Table 4 (DOCX 20 kb)

References

  1. 1.
    Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N, Sasano H (2010) Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci 101:2670–2675CrossRefPubMedGoogle Scholar
  2. 2.
    Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth C, Samonigg H, Hüttner K, Fohler H, Ruecklinger E, Jakesz R, Greil R, Austrian Breast and Colorectal Cancer Study Group (2009) Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant Benefit? Clin Breast Cancer 9(Suppl 1):S18–S27CrossRefPubMedGoogle Scholar
  3. 3.
    Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B (2011) Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res 13(6):R127CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664CrossRefPubMedGoogle Scholar
  5. 5.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59(4):225–249CrossRefPubMedGoogle Scholar
  6. 6.
    Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J (2003) A multigenic program mediating breast cancermetastasis to bone. Cancer Cell 3(6):537–549CrossRefPubMedGoogle Scholar
  7. 7.
    Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagué J (2009) Latent bone metastasis in breast cancer tied to Src dependent survival signals. Cancer Cell 16(1):67–78CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Henderson IC (1993) Risk factors for breast cancer development. Cancer Supplement 71:2127–2140CrossRefGoogle Scholar
  9. 9.
    Ma H, Bernstein L, Pike MC, Ursin G (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8:R43. doi: 10.1186/bcr1525 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270–282CrossRefPubMedGoogle Scholar
  11. 11.
    Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA (24) 289:3243–3253.Google Scholar
  12. 12.
    Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG (1983) Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature 303:767–770CrossRefPubMedGoogle Scholar
  13. 13.
    Sotiriou C, Piccart MJ (2007) Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7:545–553CrossRefPubMedGoogle Scholar
  14. 14.
    Chimge NO, Baniwal SK, Luo J, Coetzee S, Omar Khalid O, Berman B, Tripathy D, Ellis M, Frenkel B (2012) Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally-regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res 18(3):901–911CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Komori T (2010) Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 339:189–195CrossRefPubMedGoogle Scholar
  16. 16.
    Lo Coco F, Pisegna S, Diverio D (1997) The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica 82:364–370PubMedGoogle Scholar
  17. 17.
    Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, Brenner O, Berke G, Levanon D, Groner Y (2003) Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci U S A 100:7731–7736CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Levanon D, Glusman G, Bettoun D, Ben-Asher E, Negreanu V, Bernstein Y, Harris-Cerruti C, Brenner O, Eilam R, Lotem J, Fainaru O, Goldenberg D, Pozner A, Woolf E, Xiao C, Yarmus M, Groner Y (2003) Phylogenesis and regulated expression of the RUNT domain transcription factors RUNX1 and RUNX3. Blood Cells Mol Dis 30(2):161–163CrossRefPubMedGoogle Scholar
  19. 19.
    Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA, Stein JL, Lian JB, van Wijnen AJ, Stein GS (2007) Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci U S A 104:19861–19866CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    . Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, Huser C, Stein T, Neil J, Cameron ER (2010) Runx2 in normal tissues and cancer cells: a developing story. Blood Cells, Molecules & Diseases. 45 (2):117–123.Google Scholar
  21. 21.
    Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, Gabet Y (2010) Regulation of adult bone turnover by sex steroids. J Cell Physiol 224:305–310CrossRefPubMedGoogle Scholar
  22. 22.
    Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS (2005) Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A 102:1454–1459CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN, Nickerson JA, Lian JB, Stein GS (2009) Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res 69:6807–6814CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2008) Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 68:7795–7802CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B (2010) Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 9:258CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB (2010) Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811–821CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Pratap J, Lian JB, Stein GS (2011) Metastatic bone disease: role of transcription factors and future targets. Bone 48:30–36CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Zelzer E, Glotzer DJ, Hartmann C, Thomas D, Fukai N, Soker S, Olsen BR (2001) Tissue specific regulation of VEGF expression during bone development requires Cbfa1 ⁄ Runx2. Mech Dev 106 (1–2): 97–106.Google Scholar
  29. 29.
    Selvamurugan N, Kwok S, Partridge NC (2004) Smad3 interacts with JunB and Cbfa1 ⁄ Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem 279:27764–27773CrossRefPubMedGoogle Scholar
  30. 30.
    Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, Bellahcene A, Van Wijnen AJ, Young MF, Lian JB, Stein GS, Gerstenfeld LC (2003) Osteoblast-related transcription factors Runx2 (Cbfa1 ⁄ AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 63(10):2631–2637PubMedGoogle Scholar
  31. 31.
    Das K, Leong DT, Gupta A, Shen L, Putti T, Stein GS, van Wijnen AJ, Salto-Tellez M (2009) Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer 45(13):2239–2248CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Page DL, Jensen RA, Simpson JF (1998) Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat 51:195–208CrossRefPubMedGoogle Scholar
  33. 33.
    Fitzgibbons PL1, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124 (7):966–978.Google Scholar
  34. 34.
    Ellis IO, Elston CW (2006) Histologic grade (chapter 19). In: O’Malley FP, Pinder SE (eds) Breast pathology. Elsevier, Philadelphia, PA, pp. 225–233CrossRefGoogle Scholar
  35. 35.
    Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, Pinder SE, Rhodes A, Walker R (2004) Best practice no. 176: updated recommendation for HER-2 testing in the UK. J Clin Pathol 57(3):322–327.Google Scholar
  36. 36.
    Allred DC, Harvey JM, Berardo M, Clarck GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMedGoogle Scholar
  37. 37.
    Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2005) The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581–8591CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Risau W (1997) Mechanisms of angiogenesis. Nature 386:671–674CrossRefPubMedGoogle Scholar
  39. 39.
    Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, Uehira M (1999) Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 17:177–181CrossRefPubMedGoogle Scholar
  41. 41.
    Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR (1996) Evidence for a causal role of parathyroid hormonerelated protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544–1549CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Chang CH, Fan TC, Yu JC, Liao GS, Lin YC, Shih A, Li WH, Yu A (2014) The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer. J Transl Med 12:257CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2015

Authors and Affiliations

  • Saba Mohamed El-Gendi
    • 1
    Email author
  • Mohamed Farouk Mostafa
    • 2
  1. 1.Department of PathologyAlexandria Faculty of MedicineAlexandriaEgypt
  2. 2.Department of Clinical Oncology and Nuclear MedicineAlexandria Faculty of MedicineAlexandriaEgypt

Personalised recommendations